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Purpose
To review the scientific literature supporting the participation of caveolin-1 in the pathogenesis
of tissue fibrosis and that modulation of the caveolin-1 pathway may represent a novel treatment
for systemic sclerosis (SSc) and other fibrotic diseases.

Recent Findings
Caveolin-1 plays an important role in the regulation of transforming growth factor β (TGF-β)
signaling owing to its participation in TGF-β receptor (TβR) internalization. TβR internalized
through caveolin-1 lipid rafts undergoes rapid degradation, effectively decreasing TGF-β
signaling. Studies have shown that caveolin-1 knockdown in vitro markedly increased collagen
gene expression in normal human lung fibroblasts. Caveolin-1 was reduced in affected SSc
lungs and skin and in idiopathic pulmonary fibrosis (IPF) lung tissues and fibroblasts. Increasing
caveolin-1 expression markedly improved bleomycin-induced pulmonary fibrosis. Restoration
of caveolin bioavailability employing penetratin, a cell-permeable peptide carrier for a bioactive
caveolin-1 fragment abrogated TGF-β activation of cultured human dermal fibroblasts. Systemic
administration of penetratin-caveolin-1 peptide to mice with bleomycin-induced lung fibrosis
reduced fibrosis.

Summary
Caveolin-1 plays an important role in the regulation of TGF-β signaling and participates in the
pathogenesis of SSc and IPF. Restoration of caveolin function employing active caveolin-1
fragments coupled to cell-permeable carrier peptides may represent a novel approach for their
treatment.
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Introduction
Fibrotic disorders, which include systemic sclerosis (SSc), idiopathic pulmonary fibrosis (IPF),
cirrhosis of the liver, and the newly recognized Nephrogenic Systemic Fibrosis (NSF), are
characterized by abnormal and excessive deposition of collagen and other extracellular matrix
(ECM) components in various tissues [1-3].

Although their etiology is quite diverse, the

presence of ECM-producing fibroblasts displaying an activated phenotype in the affected tissues
is typical of fibrotic diseases. Fibroblast activation is characterized by a marked increase in the
transcriptional activity of the genes encoding type I and type III collagens and fibronectin,
initiation of the expression of α-smooth muscle actin (α -SMA), and the reduction of ECM
degradative activities [4]. Activated fibroblasts display contractile properties resulting from the
expression of stress fibers containing α-SMA, and their profibrotic activation is part of a
complex set of molecular and biochemical changes that are conserved for multiple passages in
vitro.

Transforming growth factor-β (TGF-β) plays a crucial role in fibroblast activation. One of the
most important effects of TGF-β is its stimulation of ECM production and accumulation by
increasing the expression of genes encoding various collagens and other matrix proteins and
reducing the expression of genes involved in ECM degradation and turnover. Delineation and
identification of the specific cellular receptors and intracellular mediators participating in the
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cellular response to TGF-β [1-3,5-10] and recognition that TGF-β is a major participant in the
initiation and progression of tissue fibrosis have recently focused substantial attention on this
growth factor as a target for the development of anti-fibrotic therapies [11-14]. Despite intensive
investigations in vitro and in various animal models of fibrosis strategies to block TGF-β effects
have thus far been ineffective or are still in the experimental stage.

In the last decade, however, a novel pathway capable of exerting a potent modulation of TGF-β
signaling has become recognized. This pathway involves the protein caveolin-1 and caveolae,
the cell membrane structures in which caveolin-1 is found.
membrane lipid rafts called caveolae co-localize TGF-β

Caveolin-1-positive plasma
receptor with its degrading

SMURF/Smad7 complex, a process which may result not only in TGF-β signal abrogation and
consequent fibroblast deactivation but potentially even in the restoration of the normal balance of
ECM production and degradation. Here, we review recent scientific literature that support the
participation of caveolin-1 in the pathogenesis of tissue fibrosis and indicate that modulation of
the TGF-β pathway by strategic management of caveolin-1 bioavailability may represent a
promising and novel therapeutic approach for fibrotic conditions such as SSc.

Caveolae microdomains are crucial regulators of receptor-mediated cellular signaling
Caveolin-1 is the most important member of a family of three membrane proteins (caveolin- 1, 2
and 3) that are the major coating proteins of caveolae. Caveolae are 50- to 100-nm flask-shaped
plasma membrane invaginations that since their discovery have provoked a multitude of
conjectures about their function [15]. Unlike earlier views of the plasma membrane as a “fluid
mosaic” [16], which posited that integral membrane proteins float and diffuse freely through a
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sea of homogeneous lipids, a current view is that membrane proteins are heterogeneously
distributed and can be found clustered within specialized microdomains, termed lipid rafts,
which are particularly rich in cholesterol and glycophosphatidylinositol-linked proteins.
Caveolae represent a morphologically identifiable subset of lipid rafts which participate in the
pathogenesis of numerous diseases [17-19], and extensive recent evidence has demonstrated the
clustering of numerous receptors within their domains. It has also been shown that the spatial
organization of cell receptors in lipid rafts and caveolae can affect the subsequent transmission of
the specific signal initiated by ligand engagement of these receptors [20-23].

Caveolin-1 regulated TGF-β signaling
Recent studies have shown that caveolin-1 plays a very important role in the regulation of TGF-β
signaling owing to its participation in TβR internalization.

TβR are internalized both by

caveolin-1 associated lipid rafts and by early endosome antigen 1 (EEA-1) non-lipid raft
pathways. It has been shown, furthermore, that non-lipid raft associated internalization increases
TGF-β signaling, whereas, caveolin-associated
caveolin
internalization increases TβR degradation thus,
effectively decreasing or abolishing TGF-β signaling [24,25]. Specifically, it was demonstrated
that SARA and SMURF, upstream regulators of either TGF-β signaling or TβR degradation,
respectively, were localized in distinct subcellular compartments [26,27]. The complex
SARA/Smad2/3 which initiates TβR-1 signaling was found localized in a non-lipid raft, EEA-1
positive compartment, whereas, the SMURF/Smad7 complex which is responsible for initiating
proteasome degradation of TβR was found localized in caveolin-1 positive lipid rafts. The
localization of the TβR in the EEA-1 positive compartment was responsible for downstream
Smad activation through recruitment and phosphorylation of Smad-2/3 and subsequent nuclear
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translocation of the Smad2/3-Smad4 complex, whereas, the localization of the TβR-I (or II) and
receptor complex in caveolae lipid rafts caused recruitment of SMURF/Smad7 and subsequent
receptor ubiquitination and rapid turnover.

This novel mechanism of regulation of the TβR function and activity follows ligand engagement
and is regulated by the fluidity of the membrane and the membrane density of the distinct
caveolin-1 and non-caveolin compartments. Thus, absence of one compartment or imbalance in
the densities of the two compartments may affect the level of TGF-β pathway activity given the
same amount of ligand binding.

Furthermore, since this process occurs at the level of

internalization of the TβR immediately following ligand engagement, it likely represents an
important mechanism of regulation of TGF-β signaling as illustrated in Figure 1. One unique
feature of this pathway is that it provides a cogent and plausible mechanism for the perpetuation
of tissue fibrosis following an initial triggering event. The triggering event results in a decrease
in caveolin-1 gene expression; this decrease then shifts TGF-β internalization through the EEA-1
pathway, leading to accentuation and perpetuation of the TGF-β-induced fibrotic effects and
simultaneously causing further downregulation of caveolin-1 gene expression. Thus, the current
evidence indicates that caveolin-1 is a crucial regulator of TGF-β intracellular signaling and TβR
endosomal degradation and, therefore, may play a key role in the pathogenesis of disorders
characterized by exaggerated tissue fibrosis.

Early evidence of the role of caveolin-1 in pathologic tissue fibrosis
The earliest evidence linking caveolin-1 to a fibrotic phenotype was provided by the study of
Kasper et al. [28] more than a decade ago. These authors demonstrated that caveolin expression
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was markedly downregulated in alveolar epithelium of rats and mini-pigs following radiationinduced lung injury. The profound downregulation of caveolin preceded the onset of radiationinduced lung fibrosis. Furthermore, the amount of immunoreactive caveolin correlated with the
severity of lung fibrosis, with normal amounts present in non-affected tissue in contrast with a
marked decrease in areas of fibrosis. The role of caveolin-1 in the development of tissue fibrosis
was confirmed in two independent studies which simultaneously reported the generation of mice
lacking caveolin-1 by gene targeting [29,30]. Drab et al. [29] showed that these mice displayed
profound histopathological and electron microscopical alterations in the lung alveolar septae,
with replacement of the normal alveolar bilayer lining by a disorganized, multilayered structure
containing abundant connective tissue. Razani et al. [30] described thickened alveolar septae,
marked hypercellularity, increased reticulin deposition and thickening of the basement
membrane.

Caveolin-1 downregulation in SSc and pulmonary fibrosis
Subsequent studies extended the early observations described above to human diseases such as
IPF and SSc. Tourkina et al. [31] demonstrated that caveolin-1 knockdown in vitro resulted in a
5-fold increase in normal human lung fibroblast collagen gene expression whereas increased
caveolin-1 expression induced by PKC-α caused a reduction in collagen production. The same
study showed that fibroblasts from affected skin or lung from SSc patients contained less
caveolin-1. More recently, additional evidence for caveolin-1 participation in pulmonary fibrosis
was presented. Wang et al. [32] observed marked reduction of caveolin-1 expression in lung
tissues and fibroblasts from IPF patients compared with controls. Furthermore, induction of
caveolin-1 expression with an adenovirus-caveolin-1 expression vector ameliorated bleomycin-
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induced pulmonary fibrosis.

These authors also showed that TGF-β 1 decreased caveolin-1

expression in human lung fibroblasts and that caveolin-1 expression suppressed TGF-β 1-induced
stimulation of ECM production in these cells. Odajima et al. [33••] examined the expression of
caveolin-1 during the development of bronchiolization, a key process in fibrosing lung, in mice
with bleomycin-induced pulmonary fibrosis and in lungs from patients with various forms of
interstitial pneumonias. The results showed a marked decrease of caveolin-1 mRNA levels in
the lungs from the bleomycin-treated mice as well as in bronchiolar epithelial cells isolated by
laser capture microdissection. Also, significant reduction in caveolin-1 protein and mRNA
levels were found in affected tissues from patients with pulmonary fibrosis. Thus, the results of
these studies collectively supported a pivotal role for caveolin-1 in the pathogenesis of
pulmonary fibrosis.

Recently our group demonstrated that caveolin downregulation is also an important feature of
SSc [34••]. In these studies we found a substantial reduction in caveolin-1 immunofluorescence
in affected SSc lungs and skin in contrast with normal caveolin-1 expression in
histopathologically non-affected areas (Figure 2). Furthermore, TGF-β treatment of normal
dermal fibroblasts induced a potent downregulation of caveolin-1 expression. These findings
suggested that the observed decrease in caveolin-1 expression in SSc affected tissues may have
been caused by TGF-β or other cytokines released by inflammatory cells present in the tissue and
could in turn be responsible for further amplification of TGF-β signaling, a crucial event in the
pathogenesis of tissue fibrosis in SSc. Specifically, as depicted in Figure 1, decreased caveolin1 expression in SSc would be responsible for an amplification loop of TGF-β signaling; the
increase in TGF-β signaling causing, in turn, a further downregulation of caveolin expression at
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both the mRNA and protein levels, triggering a repetitive cycle of signal amplification that
ultimately leads to tissue fibrosis.

Caveolin-null mice and tissue fibrosis
Early studies on caveolin-1 null mice [29,30] described thickening of lung alveolar septa caused
by proliferation of endothelial cells and accumulation of reticulin and other matrix proteins,
however, they did not describe whether the caveolin-1-null animals had evidence of fibrosis in
other tissues.

We performed an extensive histopathologic analysis and measured the

hydroxyproline content of skin and lungs of caveolin-1 knockout mice [34••]. The results
indicated that as early as 12 weeks of age, caveolin-1-null mice displayed a marked increase in
collagen deposition in skin and lungs compared with their normal littermates (Figure 3). These
histopathological changes were accompanied by a threefold increase in lung and skin collagen
content. In vitro studies performed with caveolin-1 null fibroblasts indicated that the observed
tissue fibrosis was associated with a profibrotic phenotype of tissue fibroblasts strikingly similar
to that of SSc fibroblasts. These data indicate that the lung involvement in caveolin-1-null mice
is secondary to a combination of pulmonary artery hypertension resulting from the known hyperproliferative phenotype of caveolin-1-null vascular smooth muscle cells and their increased
sensitivity to endothelin-1 [35,36] combined with parenchymal lung fibrosis caused by the
profibrotic gene expression pattern of caveolin-1 null fibroblasts.

The role of caveolin-1 in lung fibrosis has been indirectly confirmed by a study in which specific
endothelial overexpression of caveolin-1 was induced in caveolin-1 knockout mice. Selective reexpression of caveolin-1 in endothelial cells partially reverted the phenotype of pulmonary artery
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hypertension, whereas, in contrast, the extent of lung parenchymal fibrosis was not affected by
the endothelial cell-specific rescue of caveolin-1 expression [37••].

Restoration of caveolin-1 levels as a therapeutic approach for fibrotic diseases
The data summarized here provide robust evidence supporting the involvement of caveolin-1
downregulation in the pathogenesis of tissue fibrosis. The next logical step, as suggested in a
recently published editorial [38••] is to develop therapeutic tools that may increase caveolin-1
bioavailability in the target cells.

One of the most promising and novel approaches to

accomplish this goal is the utilization of cell permeable carriers capable of shuttling small
peptides and proteins inside cells [39]. One such carrier is penetratin, a 16-amino acid-long
fragment of the third helix of the homeodomain of the Antennapedia homeoprotein [40].
Penetratin is internalized by cells in a specific, non-receptor-mediated manner, and is able to
translocate through the cell membrane [40]. On the other hand, Razani et al. [41] demonstrated
previously that the interaction between caveolin-1 and the TβR was mediated by a small region
within the caveolin-1 protein identified as the caveolin scaffolding domain (CSD) which
specifically recognizes and binds to a short amino acid sequence termed the caveolin binding
motif present in TβR and other serine-threonine kinases. Numerous studies have provided ample
experimental evidence that the caveolin-1 kinase inhibitor function is mediated by the CSD
[42,43] and in some studies caveolin-1 function has been restored following successful delivery
of the CSD to cells employing a penetratin-CSD fusion cell permeable peptide.

In our studies [34••] we employed the CSD-penetratin fusion peptide to explore the effects of
caveolin-1 function restoration on the profibrotic phenotype of SSc fibroblasts and on the effects
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of exogenous TGF-β stimulation. We found that the CSD-penetratin fusion peptide was not
cytotoxic, inhibited the increased collagen production and α-SMA expression in SSc dermal
fibroblasts, and suppressed TGF-β stimulation of collagen and α-SMA expression. Furthermore,
the peptide inhibited TGF-β induced Smad2/3 nuclear translocation. Similar studies were
recently published by Tourkina et al. [44••], who, employing the same peptide on SSc lung
fibroblasts in vitro demonstrated an inhibitory effect of important non-Smad intracellular
signaling TGF-β pathways including MEK, ERK, JNK, and Akt. Of further interest was their
demonstration that systemic administration of CSD-penetratin peptide to mice with bleomycininduced lung fibrosis blocked epithelial cell apoptosis and inflammatory cell infiltration and
reduced fibrotic changes, thus supporting the potential efficacy of this treatment for SSc and
pulmonary fibrosis.

Conclusion
Numerous studies published during the last decade have provided strong evidence that caveolin1, the main protein component of caveolae, participates in the pathogenesis of fibrotic diseases
through regulation of TβR degradation and activation. A profound reduction in caveolin-1
expression has been demonstrated in affected tissues from IPF and SSc patients, and the
important role of the protein in TGF-β signaling and stimulation of ECM production has been
conclusively demonstrated. Restoration of caveolin-1 function employing novel cell-permeable
peptides coupled to active caveolin-1 fragments abrogated the profibrotic effects of TGF-β and,
therefore, may represent a novel treatment for SSc and other fibrotic disorders.
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Legends to Figures
Figure 1. Schematic diagram for the involvement of caveolae in TGF-β signal transduction and
for the mechanisms whereby caveolin-1 downregulation in SSc would result in tissue fibrosis
and further caveolin-1 downregulation (adapted from ref. 25).
Figure 2. Reduction of caveolin-1 expression in SSc lung and skin. A. Confocal image of
normal lung immunostained for caveolin-1. Note the homogeneous green membrane staining for
caveolin-1 on the surface of alveolar wall cells. B and C. Confocal image of SSc lung stained for
caveolin-1. Note that in contrast with A, there is low expression of caveolin-1 in most cells of the
vessel wall and interstitium. D. Normal skin. Note the expression of caveolin-1 surrounding
almost every cell in the dermis. E. SSc skin. Note the low expression of caveolin-1 in most cells.
F. Cell lysates from two SSc dermal fibroblast cell lines and two normal dermal fibroblast cell
lines analyzed by Western blot for caveolin-1. Reproduced from ref. 34 with permission form
Arthritis Rheum.
Figure 3. Increased collagen in lungs and skin of caveolin-1 knockout mice. A. Masson’s
Trichrome staining for collagen in interstitium of wild type (WT) and caveolin-1 null lung
(CAV). B. Masson’s Trichrome staining for collagen in the skin of wild type (WT) and
caveolin-1 null skin (CAV). Reproduced from ref. 34 with permission from Arthritis Rheum.
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